Advanced search
Publication Cover
Expert Opinion on Orphan Drugs Volume 2, 2014 - Issue 12
Submit an article Journal homepage
86
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluations

Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer

Jolanta KrajewskaM.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice Branch, Gliwice, Poland
&
Barbara JarzabM.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice Branch, Wybrzeze AK 15, 44-101 Gliwice, Poland+48 32 2789301; +48 32 2789310; [email protected]
, MD PhD
Pages 1331-1340 | Published online: 23 Sep 2014

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jolanta Krajewska, Aleksandra Kukulska & Barbara Jarzab. (2015) Drug safety evaluation of lenvatinib for thyroid cancer. Expert Opinion on Drug Safety 14:12, pages 1935-1943.
Read now
Jolanta Krajewska, Daria Handkiewicz-Junak & Barbara Jarzab. (2015) Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opinion on Pharmacotherapy 16:4, pages 573-583.
Read now

Articles from other publishers (2)

Nigel Fleeman, Rachel Houten, Adrian Bagust, Marty Richardson, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Juliet Hounsome, Rui Duarte & Aditya Shenoy. (2020) Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment 24:2, pages 1-180.
Crossref
Yvonne Hewett, Subash Ghimire, Bilal Farooqi & Binay K Shah. (2016) Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer. Journal of Oncology Pharmacy Practice 24:1, pages 28-32.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.